Mital Bhadaniaa,*, Falguni Majmudarb, M. A. Karmurc
a,*Dept. of Product Management, McLeon Pharmaceuticals, Gandhinagar, India
bDept. of Pharmacology, Smt. NHL Municipal Medical College, Ahmedabad, India
cSaurastra Diabetes Centre, Rajkot, India
*Author for correspondence
Dr. Mital Bhadania
McLeon Pharmaceuticals
B08 Ariane Casa, Opp. IOC Petrol Pump
Adalaj-382421 Gandhinagar Gujarat, India
Abstract
Objective: This study was intended to improve diabetes care among patients with type 2 diabetes mellitus with premixed insulin analogue and human premixed insulin therapy. To evaluate safety and efficacy of premixed insulin add-on to metformin and sulphonylurea in routine clinical practice. Material and methods: This was a 26 week, multi-centre, parallel group, and open label study in type 2 diabetes mellitus patients. Patients were treated at various diabetes clinic and referral clinics in Gujarat India. The data included demographic characteristics, medical history, and the treatment regimens were collected during their routine clinical visit. Results: Out of 226 patients; 177 patients were completed the study, of which 103 (58.2%) were male and 74 (41.8%) were female. The mean±SD; A1C% was 10.04 ± 1.68; age was 60.61 ± 6.96 years; duration of diabetes mellitus was 5.12 ± 3.16 years at baseline. Combination of premixed insulin analogue was significantly achieved % reduction at target of <7% A1C as compared to human premixed insulin. Premixed insulin analogue significantly reduced A1C, FBG, PPBG as compared to the dual and triple combination of human premixed insulin. Premixed insulin analogue group showed very less hypoglycemic events during the study period compared to other insulin group. Conclusion: Premixed insulin analogue lowers A1C to a greater degree and minimize the risk of hypoglycemic events in T2DM patients compared to human insulin even though poor glycemic control. Patient and physician continuous education on drug therapy will leads to achieve adequate glycemic control.
Keywords: Diabetes mellitus, Premixed insulin analogue, Human premixed insulin, Glycosylated haemoglobin
